4Q Revenues: $1.1 billion (+8%)
4Q Earnings: $5.3 million (loss of $214 million 4Q11)
FY Revenues: $4.1 billion (+1%)
FY Earnings: $44.2 million (loss of $9.4 million FY11)
Comments: Growth in the quarter was driven strong sales of Specialty Injectable Pharmaceutical (SIP) products, up 12% to $696 million, including Precedex globally and oncolytic oxaliplatin in the U.S., as well as higher volumes for certain products in the EMEA region. SIP sales in the Americas were $539.6 million, up 13%; EMEA sales were $83.3 million, up 14%; APAC sales were flat at $73.3 million.